Meihua Han
Overview
Explore the profile of Meihua Han including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
361
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sun L, Zuo C, Ma B, Liu X, Guo Y, Wang X, et al.
Chin Herb Med
. 2025 Feb;
17(1):156-165.
PMID: 39949814
Objective: In order to enhance the efficacy of anti-breast cancer, paclitaxel nanoparticles (PTX NPs) and polypyrrole nanoparticles (PPy NPs) were combined with photothermal therapy and chemotherapy. At the same time,...
2.
Sun L, Ma B, Yang F, Zou H, Guo Y, Wang X, et al.
Int J Pharm
. 2024 Dec;
670:125113.
PMID: 39710309
Compared to conventional polymer-based and biomaterial carriers, cells as vehicles for delivering bioactive molecules in the treatment of tumor diseases offer characteristics such as non-toxicity, biocompatibility, low immunogenicity, and prolonged...
3.
Lang X, Wang X, Han M, Guo Y, Dong Z
Biomed Pharmacother
. 2024 Jul;
177:117107.
PMID: 38996708
The development of new effective drugs to treat breast cancer remains a huge challenge. ABT-737 can inhibit Bcl-2 proteins to promote apoptosis. Resiquimod (R848) is a TLR7/8 agonist that is...
4.
Wang X, Liu X, Guo Y, Gong T, Lu W, Han M, et al.
Int J Nanomedicine
. 2024 May;
19:4679-4699.
PMID: 38803997
Background: Breast cancer is a heterogeneous disease globally accounting for approximately 1 million new cases annually. Chemotherapy remains the main therapeutic option, but the antitumor efficacy needs to be improved....
5.
Lang X, Wang X, Han M, Guo Y
Int J Nanomedicine
. 2024 May;
19:4533-4568.
PMID: 38799699
Until now, there has been a lack of effective strategies for cancer treatment. Immunotherapy has high potential in treating several cancers but its efficacy is limited as a monotherapy. Chemoimmunotherapy...
6.
Li M, Li H, Lu L, Fu J, Ao H, Han M, et al.
Drug Deliv Transl Res
. 2024 Feb;
14(11):3225-3238.
PMID: 38421545
Quercetin, as a representative flavonoid, is widely present in daily diet and has been developed as a dietary supplement due to its beneficial physiological activities. However, the application of quercetin...
7.
Ding L, Han M, Wang X, Guo Y
Toxins (Basel)
. 2023 Sep;
15(9).
PMID: 37755991
Ochratoxins are the secondary metabolites of and , among which ochratoxin A (OTA) is the most toxic molecule. OTA is widely found in food and agricultural products. Due to its...
8.
Fu J, Lu L, Li M, Guo Y, Han M, Guo Y, et al.
Pharmaceutics
. 2023 May;
15(5).
PMID: 37242579
Neutral/negatively charged nanoparticles are beneficial to reduce plasma protein adsorption and prolong their blood circulation time, while positively charged nanoparticles easily transverse the blood vessel endothelium into a tumor and...
9.
Lu L, Ao H, Fu J, Li M, Guo Y, Guo Y, et al.
Biomed Pharmacother
. 2023 May;
163:114870.
PMID: 37187019
Ginsenosides are the major and key components for ginseng to exert its wide and beneficial therapeutic efficacy in clinic. Meanwhile, many ginsenosides and their metabolites showed in vitro an in...
10.
Yu B, Lang X, Wang X, Ding L, Han M, Guo Y, et al.
Biomed Pharmacother
. 2023 Apr;
162:114662.
PMID: 37037095
Drug delivery systems require that carrier materials have good biocompatibility, degradability, and constructability. Poly(amino acids), a substance with a distinctive secondary structure, not only have the basic features of the...